SBH
LKFT

Segall Bryant & Hamill’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Segall Bryant & Hamill’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-426,412
Closed -$12.8M – 617
2026
Q1 		$12.8M Sell
426,412
-21,684
-5% -$718K 0.18% 192
2025
Q4 		$14.7M Sell
448,096
-39,100
-8% -$1.26M 0.2% 180
2025
Q3 		$16.9M Sell
487,196
-13,881
-3% -$444K 0.22% 158
2025
Q2 		$14M Sell
501,077
-150,384
-23% -$4.03M 0.2% 172
2025
Q1 		$16.4M Sell
651,461
-34,406
-5% -$869K 0.25% 126
2024
Q4 		$18.9M Sell
685,867
-19,781
-3% -$551K 0.26% 120
2024
Q3 		$20.3M Sell
705,648
-93,431
-12% -$2.54M 0.28% 112
2024
Q2 		$19.8M Sell
799,079
-68,963
-8% -$1.96M 0.35% 91
2024
Q1 		$28M Sell
868,042
-6,686
-0.8% -$249K 0.52% 55
2023
Q4 		$35.6M Buy
874,728
+136,737
+19% +$5.03M 0.69% 36
2023
Q3 		$25.5M Buy
737,991
+346,630
+89% +$13.5M 0.3% 105
2023
Q2 		$15.9M Buy
391,361
+91,970
+31% +$3.75M 0.17% 160
2023
Q1 		$11.6M Buy
+299,391
New +$12.3M 0.12% 207

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Segall Bryant & Hamill's LKFT Position: Q2 2026 in Review

Segall Bryant & Hamill sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2026, closing a stake of 426,412 shares — an estimated $12.8M sold.

Segall Bryant & Hamill first reported a position in LKFT in Q1 2023 and held it in 13 quarters. The position peaked at $35.6M in Q4 2023. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Segall Bryant & Hamill reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2026 after selling out during the quarter.
  • Segall Bryant & Hamill sold 426,412 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $12.8M.
  • Segall Bryant & Hamill first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2023 and held it in 13 quarters.
  • Segall Bryant & Hamill's Lakefront Biotherapeutics American Depositary Shares position peaked at $35.6M in Q4 2023.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.